|
1
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcomaPediatric and Adolescent Osteosarcoma. Jaffe N,
Bruland OS and Bielack S: 152. Springer; US: pp. 3–13. 2010,
View Article : Google Scholar
|
|
2
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment-where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kansara M, Teng MW, Smyth MJ and Thomas
DM: Translational biology of osteosarcoma. Nat Rev Cancer.
14:722–735. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Salah S, Ahmad R, Sultan I, Yaser S and
Shehadeh A: Osteosarcoma with metastasis at initial diagnosis:
Current outcomes and prognostic factors in the context of a
comprehensive cancer center. Mol Clin Oncol. 2:811–816. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Subbiah V and Kurzrock R: Phase 1 clinical
trials for sarcomas: The cutting edge. Curr Opin Oncol. 23:352–360.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang J and Zhang W: New molecular insights
into osteosarcoma targeted therapy. Curr Opin Oncol. 25:398–406.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kallijärvi J, Avela K, Lipsanen-Nyman M,
Ulmanen I and Lehesjoki AE: The TRIM37 gene encodes a peroxisomal
RING-B-box-coiled-coil protein: Classification of mulibrey nanism
as a new peroxisomal disorder. Am J Hum Genet. 70:1215–1228. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hämäläinen RH, Mowat D, Gabbett MT,
O'brien TA, Kallijärvi J and Lehesjoki AE: Wilms' tumor and novel
TRIM37 mutations in an Australian patient with mulibrey nanism.
Clin Genet. 70:473–479. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jagiello P, Hammans C, Wieczorek S, Arning
L, Stefanski A, Strehl H, Epplen JT and Gencik M: A novel splice
site mutation in the TRIM37 gene causes mulibrey nanism in a
Turkish family with phenotypic heterogeneity. Hum Mutat.
21:630–635. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kallijärvi J, Lahtinen U, Hämäläinen R,
Lipsanen-Nyman M, Palvimo JJ and Lehesjoki AE: TRIM37 defective in
mulibrey nanism is a novel RING finger ubiquitin E3 ligase. Exp
Cell Res. 308:146–155. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bhatnagar S, Gazin C, Chamberlain L, Ou J,
Zhu X, Tushir JS, Virbasius CM, Lin L, Zhu LJ, Wajapeyee N and
Green MR: TRIM37 is a new histone H2A ubiquitin ligase and breast
cancer oncoprotein. Nature. 516:116–120. 2014.PubMed/NCBI
|
|
12
|
Jiang J, Yu C, Chen M, Tian S and Sun C:
Over-expression of TRIM37 promotes cell migration and metastasis in
hepatocellular carcinoma by activating Wnt/β-catenin signaling.
Biochem Biophys Res Commun. 464:1120–1127. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cai Y, Cai T and Chen Y: Wnt pathway in
osteosarcoma, from oncogenic to therapeutic. J Cell Diochem.
115:625–631. 2014. View Article : Google Scholar
|
|
14
|
Anastas JN and Moon RT: WNT signalling
pathways as therapeutic targets in cancer. Nat Rev Cancer.
13:11–26. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mora-Blanco EL, Mishina Y, Tillman EJ, Cho
YJ, Thom CS, Pomeroy SL, Shao W and Roberts CW: Activation of
β-catenin/TCF targets following loss of the tumor suppressor SNF5.
Oncogene. 33:933–938. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tetsu O and McCormick F: β-Catenin
regulates expression of cyclin D1 in colon carcinoma cells. Nature.
398:422–426. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li YJ, Wei ZM, Meng YX and Ji XR:
Beta-catenin up-regulates the expression of cyclinD1, c-myc and
MMP-7 in human pancreatic cancer: Relationships with carcinogenesis
and metastasis. World J Gastroenterol. 11:2117–2123. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Trierweiler C, Blum HE and Hasselblatt P:
The transcription factor c-Jun protects against liver damage
following activated β-catenin signaling. PLoS One. 7:e406382012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiang J, Tian S, Yu C, Chen M and Sun C:
TRIM37 promoted the growth and migration of the pancreatic cancer
cells. Tumor Biol. 37:2629–2634. 2016. View Article : Google Scholar
|
|
20
|
Wang Y, Guo Q, Zhao Y, Chen J, Wang S, Hu
J and Sun Y: BRAF-activated long non-coding RNA contributes to cell
proliferation and activates autophagy in papillary thyroid
carcinoma. Oncol Lett. 8:1947–1952. 2014.PubMed/NCBI
|
|
21
|
Flahaut M, Meier R, Coulon A, Nardou KA,
Niggli FK, Martinet D, Beckmann JS, Joseph JM, Mühlethaler-Mottet A
and Gross N: The Wnt receptor FZD1 mediates chemoresistance in
neuroblastoma through activation of the Wnt/beta-catenin pathway.
Oncogene. 28:2245–2256. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Noda T, Nagano H, Takemasa I, Yoshioka S,
Murakami M, Wada H, Kobayashi S, Marubashi S, Takeda Y, Dono K, et
al: Activation of Wnt/beta-catenin signalling pathway induces
chemoresistance to interferon-alpha/5-fluorouracil combination
therapy for hepatocellular carcinoma. Br J Cancer. 100:1647–1658.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hsieh IS, Chang KC, Tsai YT, Ke JY, Lu PJ,
Lee KH, Yeh SD, Hong TM and Chen YL: MicroRNA-320 suppresses the
stem cell-like characteristics of prostate cancer cells by
down-regulating the Wnt/beta-catenin signaling pathway.
Carcinogenesis. 34:530–538. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hämäläinen RH, Avela K, Lambert JA,
Kallijärvi J, Eyaid W, Gronau J, Ignaszewski AP, McFadden D, Sorge
G, Lipsanen-Nyman M and Lehesjoki AE: Novel mutations in the TRIM37
gene in Mulibrey Nanism. Hum Mutat. 23:5222004. View Article : Google Scholar
|
|
25
|
Kumpf M, Hämäläinen RH, Hofbeck M and
Baden W: Refractory congestive heart failure following delayed
pericardectomy in a 12-year-old child with Mulibrey nanism due to a
novel mutation in TRIM37. Eur J Pediatr. 172:1415–1418. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wickström M, Dyberg C, Milosevic J, Einvik
C, Calero R, Sveinbjörnsson B, Sandén E, Darabi A, Siesjö P, Kool
M, et al: Wnt/β-catenin pathway regulates MGMT gene expression in
cancer and inhibition of Wnt signalling prevents chemoresistance.
Nat Commun. 6:89042015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma Y, Ren Y, Han EQ, Li H, Chen D, Jacobs
JJ, Gitelis S, O'Keefe RJ, Konttinen YT, Yin G and Li TF:
Inhibition of the Wnt-β-catenin and Notch signaling pathways
sensitizes osteosarcoma cells to chemotherapy. Biochem Biophys Res
Commun. 431:274–279. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:pp. 15545–15550. 2005;
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mootha VK, Lindgren CM, Eriksson KF,
Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E,
Ridderstråle M, Laurila E, et al: PGC-1alpha-responsive genes
involved in oxidative phosphorylation are coordinately
downregulated in human diabetes. Nat Genet. 34:267–273. 2003.
View Article : Google Scholar : PubMed/NCBI
|
